Zanzalintinib and nivolumab showed a 63% response rate and 18.5-month median PFS in stage 4 RCC. The study included patients with advanced RCC, treated with zanzalintinib plus nivolumab or ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...

Panelist discusses how urologists can benefit from adopting newer treatment modalities like aqua ablation for BPH, emphasizing its growing popularity, ease of learning, and efficiency in improving ...

A recent study by Moyer et al (2025) provides real-world data on the efficacy and safety of nadofaragene firadenovec in patients with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC).

The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant radiographic ...

Sasanlimab combined with BCG improved event-free survival in high-risk NMIBC patients, particularly those with CIS and T1 tumors. Subgroup analyses showed EFS benefits across different disease stages, ...

Prostate-specific membrane antigen (PSMA) expression in renal cell carcinoma (RCC) was an incidental finding but shows potential. Uncertainty regarding frequency of PSMA expression across RCC subtypes ...

Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency. Dr Shore provided guidance ...

Paul E. Dato, MD, discusses how the absence of genetic alterations in the second case makes the patient ineligible for PARP inhibitor therapy until castration resistance develops, with focus remaining ...

The test demonstrated comparable or superior performance in Black and Non-White men. IsoPSA demonstrated comparable or superior diagnostic performance in Black and non-White men, underscoring its ...

Combining reduced-dose olaparib with radium-223 improved rPFS in mCRPC patients, especially those without prior docetaxel and limited bone metastases. The combination's efficacy is based on mechanisms ...